Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00904826 · ClinicalTrials.gov registry record · Phase 1
An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica
A Phase 1 study of Neuromyelitis Optica and Devic's Disease, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
- 2
- Study locations
NCT00904826: Completed Phase 1 study of Neuromyelitis Optica and Devic's Disease, sponsored by Mayo Clinic.
NCT00904826 is a Phase 1 study of Neuromyelitis Optica and Devic's Disease that has completed, run by Mayo Clinic. The registered enrollment target is 14 participants, below the 512-participant average among 7 other Neuromyelitis Optica trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00904826, a Phase 1 study of Neuromyelitis Optica and Devic's Disease, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to determine if the drug eculizumab reduces the attack rate and improves outcome in patients with neuromyelitis optica.
Conditions Studied
Interventions
- DRUG Eculizumab
Study Locations (2)
Arizona
- Mayo Clinic - Scottsdale
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2009-04 |
| Est. Completion | 2011-12 |
| Phase | Phase 1 |
What the finished NCT00904826 record still lists
NCT00904826 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 512-participant average among 7 other Neuromyelitis Optica trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Neuromyelitis Optica appearing as the primary indexed condition, and to 1 intervention - of which Eculizumab is the first listed.
NCT00904826 reports a single indexed study location in Arizona, Minnesota.
Frequently Asked Questions
What is clinical trial NCT00904826 about?
NCT00904826 is a clinical study titled "An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica". The purpose of this study is to determine if the drug eculizumab reduces the attack rate and improves outcome in patients with neuromyelitis optica.
What is the current status of trial NCT00904826?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2009-04. Estimated completion is 2011-12.
What conditions does trial NCT00904826 study?
This clinical trial studies the following conditions: Neuromyelitis Optica, Devic's Disease.
What interventions are being tested in trial NCT00904826?
The interventions under investigation include: Eculizumab (DRUG).
Who is sponsoring clinical trial NCT00904826?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00904826 being conducted?
This trial has 2 study locations across Arizona, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuromyelitis Optica
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Tolerability of Rituximab in Neuromyelitis Optica
COMPLETED · Phase 1
-
Study of the Clinical and Radiological Impact of Ravulizumab in People With Neuromyelitis Optica Spectrum Disorder
RECRUITING
-
Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD
RECRUITING · NA
-
The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders
ACTIVE NOT RECRUITING
-
Biobank For MS And Other Demyelinating Diseases
ACTIVE NOT RECRUITING
-
A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic's Disease)
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia